Ambrx Provides Update On APEX-01, An On-Going Phase 1/2 Dose Escalation Study Evaluating ARX517, A Proprietary PSMA-Targeting ADC, In Metastatic Castration-Resistant Prostate Cancer
Ambrx Provides Update On APEX-01, An On-Going Phase 1/2 Dose Escalation Study Evaluating ARX517, A Proprietary PSMA-Targeting ADC, In Metastatic Castration-Resistant Prostate Cancer
Ambrx 提供了 APEX-01 的最新進展,這是一項正在進行的第 1/2 階段劑量遞增研究,該研究評估了專有的靶向 PSMA 的 ADC 在轉移性耐去勢前列腺癌中的應用 ARX517
- Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed
- Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose
- 在 3.4 mg/kg(隊列 9)的 21 天觀察期結束後,未觀察到劑量限制毒性(DLT)或嚴重不良事件(SAE)
- 第 9 隊列中的兩名患者在第一劑 ARX517 劑量治療後三週內PSA迅速降低
Cohort 8
第 8 組
-
The cohort (2.88 mg/kg) is now fully enrolled with 20 patients
-
該隊列(2.88 mg/kg)現已完全入組,有20名患者
Recommended phase 2 dose expected by early next year
第二階段的推薦劑量預計將於明年初推出
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。